ProPhase Labs, Inc. (PRPH) financial statements (2021 and earlier)

Company profile

Business Address 621 N. SHADY RETREAT ROAD
DOYLESTOWN, PA 18901
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1822023
Cash and cash equivalents023023
Short-term investments1719   
Receivables232646
Inventory, net of allowances, customer advances and progress billings122343
Inventory122343
Prepaid expense  001 
Assets held-for-sale, not part of disposal group  0  
Other undisclosed current assets553011
Total current assets:101828101213
Noncurrent Assets
Property, plant and equipment223333
Other undisclosed noncurrent assets  3   
Total noncurrent assets:225333
TOTAL ASSETS:122134131516
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities031535
Accounts payable001211
Accrued liabilities  0334
Employee-related liabilities     0
Interest and dividends payable 3    
Debt   1  
Other liabilities011011
Other undisclosed current liabilities00   (0)
Total current liabilities:142755
Noncurrent Liabilities
Long-term debt and lease obligation    1 
Long-term debt, excluding current maturities    1 
Liabilities, other than long-term debt, including:0    0
Deferred revenue0
Other undisclosed liabilities, other than long-term debt     0
Total noncurrent liabilities:0   10
Total liabilities:142765
Stockholders' equity
Stockholders' equity attributable to parent1117326911
Common stock000000
Treasury stock, value(47)(47)(47)(31)(31)(31)
Additional paid in capital605958565655
Accumulated other comprehensive loss(0)(0)(0)   
Retained earnings (accumulated deficit)(2)521(20)(17)(13)
Total stockholders' equity:1117326911
TOTAL LIABILITIES AND EQUITY:122134131516

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues101310212122
Revenue, net10212122
Cost of revenue
(Cost of Goods and Services Sold)
(7)(8)(8)(11)(8)(8)
Gross profit:352101214
Operating expenses(6)(6)(6)(13)(16)(22)
Other operating income, net  0   
Operating loss:(3)(2)(4)(3)(4)(8)
Nonoperating income0 0   
Investment income, nonoperating0     
Other nonoperating income  0   
Interest and debt expense  (0)(0)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(3)(2)(4)(3)(4)(8)
Other undisclosed income from continuing operations before income taxes 00000
Loss from continuing operations before income taxes:(3)(1)(4)(3)(4)(8)
Income tax expense (benefit) (0)1  3
Loss from continuing operations:(3)(2)(2)(3)(4)(5)
Income (loss) from discontinued operations(0)(0)43   
Net income (loss):(3)(2)41(3)(4)(5)
Other undisclosed net loss attributable to parent     (3)
Net income (loss) available to common stockholders, diluted:(3)(2)41(3)(4)(8)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(3)(2)41(3)(4)(5)
Comprehensive income (loss):(3)(2)41(3)(4)(5)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)   
Comprehensive income (loss), net of tax, attributable to parent:(3)(2)41(3)(4)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: